Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

ConclusionIn our opinion, a detailed evaluation and appropriate interpretation of clinical and laboratory data in such a category of patients seem to be extremely important, especially when a decision about the TKI change due to therapy failure is considered.

Source: Clinical and Laboratory Haematology - March 6, 2018 Category: Hematology Authors: K. Lewandowski, M. Gniot, M. Wojtaszewska, Z. Kandu ła, R. Becht, E. Paczkowska, E. Mędraś, E. Wasilewska, M. Iwoła Tags: ORIGINAL ARTICLE Source Type: research